松元 美奈子 (マツモト ミナコ)

Matsumoto Minako

写真a

所属(所属キャンパス)

医学部 衛生学公衆衛生学教室 (信濃町)

職名

助教(有期)

経歴 【 表示 / 非表示

  • 2014年04月
    -
    2016年03月

    薬学部, 付属薬局, 薬剤師

  • 2018年04月
    -
    2019年04月

    医学部, 衛生学公衆衛生学教室, 特任助教

  • 2019年05月
    -
    継続中

    医学部, 衛生学公衆衛生学教室, 助教

学歴 【 表示 / 非表示

  • 2008年04月
    -
    2014年03月

    慶應義塾大学, 薬学部, 薬学科

    大学, 卒業

  • 2016年04月
    -
    2018年03月

    慶應義塾大学, 健康マネジメント研究科, スポーツマネジメント専修

    大学院, 卒業, 修士

学位 【 表示 / 非表示

  • 修士(公衆衛生学), 慶應義塾大学, 課程, 2018年03月

  • 博士(医学), 慶應義塾大学, 論文, 2025年03月

免許・資格 【 表示 / 非表示

  • 薬剤師免許, 2014年03月

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 衛生学、公衆衛生学分野:実験系を含む

  • ライフサイエンス / 衛生学、公衆衛生学分野:実験系を含まない

研究キーワード 【 表示 / 非表示

  • メタボロミクス 予防医学 公衆衛生

  • 薬剤疫学

 

著書 【 表示 / 非表示

論文 【 表示 / 非表示

  • Validity assessment of self-reported medication use for hypertension, diabetes, and dyslipidemia in a pharmacoepidemiologic study by comparison with health insurance claims

    Matsumoto M., Harada S., Iida M., Kato S., Sata M., Hirata A., Kuwabara K., Takeuchi A., Sugiyama D., Okamura T., Takebayashi T.

    Journal of Epidemiology (Journal of Epidemiology)  31 ( 9 ) 495 - 502 2021年

    研究論文(学術雑誌), 筆頭著者, 査読有り,  ISSN  1349-9092

     概要を見る

    Background: Although self-reported questionnaires are widely employed in epidemiologic studies, their validity has not been sufficiently assessed. The aim of this study was to evaluate the validity of a self-reported questionnaire on medication use by comparison with health insurance claims and to identify individual determinants of discordance in the Tsuruoka Metabolomics Cohort Study. Methods: Participants were 2,472 community-dwellers aged 37 to 78 years from the Tsuruoka Metabolomics Cohort Study. Information on lifestyle and medications was collected through a questionnaire. Sensitivity and specificity were determined using health insurance claims from November 2014 to March 2016, which were used as a standard. Potential determinants of discordance were assessed using multivariable logistic regression. Results: The self-reported questionnaire on medication use showed high validity. Sensitivity and specificity were 0.95 (95% CI, 0.93–0.96) and 0.97 (95% CI, 0.96–0.98) for antihypertensive medications, 0.94 (95% CI, 0.91–0.97) and 0.98 (95% CI, 0.98–0.99) for diabetes medications, and 0.84 (95% CI, 0.82–0.87) and 0.98 (95% CI, 0.97–0.99) for dyslipidemia medications, respectively. Males without high education and those who currently smoke cigarettes were found to be associated with discordant reporting which affected sensitivity, especially those with medication use for dyslipidemia. Conclusions: In this population-based cohort study, we found that the self-reported questionnaire on medication use was a valid measure to capture regular medication users. Sensitivity for dyslipidemia medications was lower than those for the other medications. Type of medication, sex, education years, and smoking status influenced discordance, which affected sensitivity in self-reporting.

  • Genome-wide association study of plasma amino acids and Mendelian randomization for cardiometabolic traits

    Toki R., Fushiki S., Kojima S., Sutoh Y., Otsuka-Yamasaki Y., Harada S., Iida M., Hirata A., Miyagawa N., Matsumoto M., Edagawa S., Miyake A., Kuwabara K., Hirayama A., Sugimoto M., Sato A., Amano K., Soga T., Tomita M., Arakawa K., Kinoshita K., Sakurai-Yageta M., Tamiya G., Ohmomo H., Shimizu A., Okamura T., Takebayashi T.

    Scientific Reports 15 ( 1 )  2025年12月

     概要を見る

    Plasma amino acids (AAs) have emerged as promising biomarkers for metabolic disorders, yet their causality remains unclear. We aimed to investigate the genetic determinants of AA levels in a cohort of 10,333 individuals and their causal effects on cardiometabolic traits using Mendelian randomization (MR). Plasma levels of 20 AAs were quantified using capillary electrophoresis mass spectrometry. Genome-wide association studies were conducted using BOLT-LMM and heritability estimation via LDSC analysis. Causal effects of AAs on 11 cardiometabolic traits were examined using two-sample MR analyses. We identified 85 locus-metabolite associations across 43 genes for 18 AAs, including 44 novel loci linked to metabolic genes. Heritability for AAs was estimated at 16%. MR analysis demonstrated cystine to positively associate with systolic blood pressure (SBP) (β = 0.056, SE = 0.010), while serine indicated protective effects on SBP (β = − 0.040, SE = 0.011), diastolic BP (β = − 0.044, SE = 0.010), and coronary artery disease (odds ratio 0.888, SE = 0.028). We identified potentially novel genetic loci associated with AA levels and demonstrated robust causal associations between several AAs and cardiometabolic traits. These findings reinforce the importance of AAs as potential biomarkers and therapeutic targets in cardiometabolic health.

  • Causal relationship between body mass index and insulin resistance: Linear and nonlinear Mendelian randomization study in a Japanese population

    Ishida N., Harada S., Toki R., Hirata A., Matsumoto M., Miyagawa N., Iida M., Edagawa S., Miyake A., Kuwabara K., Shibuki T., Kato S., Arakawa K., Kinoshita K., Sakurai-Yageta M., Tamiya G., Nagashima K., Muraoka H., Sato Y., Takebayashi T.

    Journal of Diabetes Investigation 16 ( 7 ) 1305 - 1314 2025年07月

    ISSN  20401116

     概要を見る

    Aims/Introduction: Obesity is a known risk factor for several chronic diseases, including type 2 diabetes mellitus, which results from increased insulin resistance and impaired insulin secretion. However, the association between obesity and insulin resistance in Asian populations has not yet been fully elucidated. Therefore, we aimed to investigate the causal relationship between body mass index (BMI) and glycemic traits using Mendelian randomization (MR). Materials and Methods: We performed individual-level MR analyses using genetic risk scores based on BMI-related variants in 3,745 individuals without diabetes mellitus from a Japanese cohort. We examined heterogeneity through subgroup analyses based on potential modifiers and determined the shape of the causal relationship using nonlinear MR analyses to further assess the impact of BMI on the homeostasis model assessment of insulin resistance (HOMA-IR). Results: MR analyses revealed a significant positive association between BMI and HOMA-IR (β = 0.077; 95% confidence interval, 0.014–0.141; P = 0.016; outcome variable was log-transformed and standardized). Additional analyses revealed heterogeneity among subgroups differentiated by age, sex, lifestyle habits, and cardiometabolic traits. Nonlinear MR analyses suggested a potential J-shaped causal relationship between BMI and HOMA-IR. Conclusions: Our findings demonstrated that obesity and low BMI may contribute to increased insulin resistance. Furthermore, the impact of BMI on insulin resistance could vary owing to effect modification. Managing BMI is crucial in individuals at high risk of increased insulin resistance and may have important implications for preventing type 2 diabetes, especially given the low insulin secretory capacity observed in East Asian populations.

  • Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan

    Matsumoto M., Kumazawa R., Ishii-Watabe A., Horiguchi I., Mamiya H., Shibata H., Saito Y., Adomi M., Taniguchi Y., Komiyama J., Sakai R., Iwagami M.

    Therapeutic Innovation and Regulatory Science 2025年

    ISSN  21684790

     概要を見る

    Purpose: To describe the temporal trends in the prescription of biologics in Japan, with additional analysis focusing on switching from original biologics to biosimilars at the individual and institutional levels. Methods: Using the JMDC claims database from January 2005 to May 2024, we identified patients who received at least one prescription for 17 biologics (original biologics or biosimilars). We elucidated the monthly trends in the proportions of original biologics and biosimilars. We also estimated the proportion of patients receiving original biologics only, those receiving biosimilars only, and those switching from original biologics to biosimilars (and vice versa) during the study period. Finally, we estimated the proportion of medical institutions that started prescribing biosimilars during the study period based on the type of medical institution. Results: Temporal trends in the proportions of original biologics and biosimilars varied widely. In May 2024, the proportion of biosimilar prescriptions was 13.6% for somatropin and 92.5% for filgrastim. At the individual level, the proportion of patients switching from original biologics to biosimilars was low (1.2–14.0%), indicating that switches do not often occur within the same patient, while more recent new users of biologics start biosimilars. At the institutional level, university-related hospitals and clinics were more and less likely, respectively to introduce biosimilars than public and other types of hospitals. Conclusion: Temporal trends in the prescription of biosimilars and switching patterns varied widely by the type of biologics. The type of medical institution should be considered when assessing and promoting the use of biosimilars. Further research and strategies to increase the use of biosimilars in clinics may be needed.

  • Evaluation of Medication Adherence Among Prevalent Users in Hypertension, Dyslipidemia, and Diabetes Using Health Insurance Claims: A Population-Based Cohort Study in Japan

    Matsumoto M., Harada S., Ikuta H., Iida M., Kato S., Sata M., Shibuki T., Ishibashi Y., Miyagawa N., Hisamatsu M., Hirata A., Kuwabara K., Takeuchi A., Sugiyama D., Suzuki S., Nakamura T., Okamura T., Takebayashi T.

    Pharmacoepidemiology and Drug Safety 33 ( 8 )  2024年08月

    ISSN  10538569

     概要を見る

    Purpose: Hypertension (HT), dyslipidemia (DL), and diabetes mellitus (DM) are major risk factors for cardiovascular diseases. Despite the wide availability of medications to reduce this risk, poor adherence to medications remains an issue. The aim of this study is to evaluate medication adherence of prevalent users in these disease medications (HT, DL, DM) using claims data. Factors associated with non-adherence were also examined. Methods: Of 7538 participants of the Tsuruoka Metabolomics Cohort Study, 3693 (HT: 2702, DL: 2112, DM: 661) were identified as prevalent users of these disease medications. Information on lifestyle was collected through a questionnaire. Adherence was assessed by a proportion of days covered (PDC) and participants with PDC ≥0.8 were defined as adherent. Predictors of non-adherence were determined by performing multivariable logistic regression. Results: Medication adherence differed by treatment status. Among those without comorbidities, those with HT-only showed the highest adherence (90.2%), followed by those with DM-only (81.2%) and those with DL-only (80.8%). Factors associated with non-adherence in each medication group were skipping breakfast and poor understanding of medications among those with HT medications, females, having comorbidities, having a history of heart disease, and drinking habit among those with DL medications, and good sleep quality and skipping breakfast among those with DM medications. Conclusion: While participants showed high medication adherence, differences were observed across medication groups. The identified predictors of non-adherence could help target those in need of adherence support.

全件表示 >>

研究発表 【 表示 / 非表示

  • 生活習慣病を有する地域在住者の自覚的健康観に影響を与える日常生活活動・健康行動の研究

    濱田蘭奈, 松元美奈子, 地引綾, 横山雄太, 鈴木小夜, 中村智徳, 武林亨

    日本薬学会第145年会(福岡), 

    2025年03月

    ポスター発表

  • 健診において気流閉塞を認めた地域在住者の実態の検討:鶴岡メタボロームコホート研究

    松元美奈子,原田成,飯田美穂,平田あや,宮川尚子,桑原和代,土岐了大,枝川俊,三宅温子,杉山大典,岡村智教,武林亨

    2023年11月

    ポスター発表

  • Factors associated with failure to undergo secondary examinations after an annual checkup from population-based cohort study(Tsuruoka Metabolomics Cohort Study)

    Minako Matsumoto, Sei Harada, Miho Iida, Aya Hirata, Kazuyo Kuwabara, Naoko Miyagawa, Tomonori Okamura, Toru Takebayashi

    第33回日本医療薬学会年会, 

    2023年11月

    口頭発表(一般)

  • お薬手帳と比較した自記式質問紙による服薬情報の妥当性研究

    矢嶋里菜,松元美奈子,原田成,飯田美穂,平田あや,桑原和代,宮川尚子,中村智徳,岡村智教,武林亨

    第82回日本公衆衛生学会総会, 

    2023年10月
    -
    2023年11月

    ポスター発表

  • 健診における受診勧奨に基づく国保・後期高齢者の二次健診受診要因の検討

    松元美奈子、原田成、飯田美穂、加藤寿寿華、佐田みずき、平田あや、宮川尚子、桑原和代、杉山大典、岡村智教、武林亨

    第33回日本疫学会学術総会 (アクトシティ浜松(浜松市)) , 

    2023年02月

    ポスター発表

全件表示 >>

競争的研究費の研究課題 【 表示 / 非表示

  • 薬局におけるPHR活用方法とその推進に関する実証的研究

    2025年04月
    -
    2027年03月

    厚生労働省 , 令和7年度厚生労働科学研究費補助金, 補助金,  研究分担者

  • バイオ後続品の有効性・安全性をリアルワールドで体系的に評価するシステムの確立

    2024年10月
    -
    2025年03月

    厚生労働省 , 令和6年度厚生労働行政推進調査事業費補助金(厚生労働科学特別研究事業), 補助金,  研究分担者

  • 健診における受診勧奨に基づく国保・後期高齢者の二次健診受診要因の検討

    2021年10月
    -
    2022年09月

    医療経済研究機構, 松元 美奈子, その他,  研究代表者

  • スタチン使用による糖尿病発症リスクに関するメタボローム疫学研究

    2019年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 松元 美奈子, 研究活動スタート支援, 補助金,  研究代表者

  • スタチン使用による糖尿病発症リスクに関するメタボローム疫学研究

    2018年10月
    -
    継続中

    文部科学省・日本学術振興会, 科学研究費助成事業, 松元 美奈子, 研究活動スタート支援, 補助金,  研究代表者

受賞 【 表示 / 非表示

  • 学生優秀発表賞

    濱田蘭奈, 松元美奈子, 地引綾, 横山雄太, 鈴木小夜, 中村智徳, 武林亨, 2025年04月, 日本薬学会第145年会, 生活習慣病を有する地域在住者の自覚的健康観に影響を与える日常生活活動・健康行動の研究

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 学生優秀発表賞

    幾田 遥史、松元 美奈子、地引 綾、横山 雄太、河添 仁、鈴木 小夜、中村 智徳、武林 亨, 2021年03月, 日本薬学会第141年会, 高齢者における三大生活習慣病と服薬アドヒアランスの検討

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • Spotlight poster presentation

    Minako Matsumoto, Sei Harada, Miho Iida, Tomonori Okamura, Toru Takebayashi, 2019年10月, 12th ISPE ACPE Conference, Validity assessment of self-reported medication use in a pharmacoepidemiology research (by comparing to medical and pharmacy insurance claims)

    受賞区分: 国際学会・会議・シンポジウム等の賞

 

担当授業科目 【 表示 / 非表示

  • 医学統計・医療情報

    2025年度

  • 三学部合同教育

    2024年度, その他, 学部専門科目, 実習・実験

  • 衛生学Ⅰ

    2023年度, 秋学期, 学部専門科目, 講義

  • 衛生学Ⅱ

    2023年度, 秋学期, 学部専門科目, 講義

  • 公衆衛生学Ⅱ

    2023年度, 秋学期, 学部専門科目, 実習・実験

全件表示 >>

 

社会活動 【 表示 / 非表示

  • 鶴岡みらい健康づくり活動

    2017年
    -
    継続中

所属学協会 【 表示 / 非表示

  • 医療経済学会, 

    2021年09月
    -
    継続中
  • 日本産業衛生学会, 

    2018年04月
    -
    継続中
  • 日本薬剤疫学会, 

    2018年
    -
    継続中
  • 日本循環器予防学会, 

    2018年
    -
    継続中
  • 日本動脈硬化学会, 

    2018年
    -
    継続中

全件表示 >>

委員歴 【 表示 / 非表示

  • 2025年04月
    -
    継続中

    Asian Conference Pharmacoepidemiology Program Committee

  • 2023年12月
    -
    継続中

    日本薬剤疫学会 拡充委員会

  • 2023年08月
    -
    継続中

    日本薬剤疫学会, Webサイトリニューアルタスクフォースの委員